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2,4-DISULFONYL PHENYL BUTYL 
NITRONE, ITS SALTS, AND THEIR USE AS 
1 
PHARMACEUTICALS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
The present application is a divisional application of 
application Ser. No. 08/173,579, ?led Dec. 23, 1993. 
BACKGROUND INFORMATION 
This invention relates to a particular nitrone compound 
and its salts and their advantageous use as pharmaceutical 
nitrone free radical trapping agents. 
BACKGROUND INFORMATION 
Alpha-phenyl tert butyl nitrone 
or “PBN“) was identi?ed in the 1970s as a useful analytical 
reagent to be used in conjunction with electron spin reso 
nance (“ESR”) to aid in the detection of free radicals, PBN 
was found to react with certain free radicals and generate a 
chemical species yielding a characteristic ESR spectrum and 
thus making it possible to determine the presence or absence 
of free radicals. 
In the late 1970s and early 1980s the medical community 35 
began to focus on the roles played by free radicals in 
diseases such as heart attacks, strokes and the like. PBN was 
used increasingly in vitro to provide analytical evidence of 
the presence of free radicals in these settings. It was also 
later administered in vivo in animal models, again as an 
analytical adjunct in attempts to observe free radicals during 
ischemia simulations and the like. 
In the mid 1980s, the ?rst possible therapeutic effects of 
PBN were implied when severe trauma ischernia animal 
tests showed that PBN-treated animals were more likely to 
survive than controls. 
On May 2, 1991, PCT patent application WO—9l-05552 
was published. This patent application, which in part cor— 
responds to now-issued U.S. Pat. Nos. 5,825,032 and 5,036, 
097, described PBN and a family of PBN derivatives de?ned 
by the formula 
wherein 
X is phenyl o 
where R is H 
(011)" 
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and n is a whole integer from 1 to 5 or 
and Y is tert-butyl or a hydroxylated or acetylated tert-butyl 
or a substituted phenyl. These compounds were proposed as 
pharmaceutical agents to treat the aftermath of stroke and 
other conditions reported to be associated with free radical 
damage. 
In 1992 a second PCT patent application was ?led 
directed to PBN ant related compounds and their medical 
30 use. This application, based on prior U.S. patent application 
Ser. No. 716,952 (?led Jun. 18, 1991), was published on 
Dec. 23, 1992 as WO 92122290. This 1992 publication 
provided two extremely broad and general disclosures. First, 
it attempted to describe as many disease states as possible 
which were associated with free radicals. These ranged from 
CNS conditions (including stroke, aging, migraine, etc.) 
through peripheral organ disease (including atherosclerosis, 
bed sores, wounds, and muscle overexertion) through UV 
40 exposure, to mention but a few highlights. Second, it 
attempted to list as many potential spin traps as possible. 
In addition to a whole range of non-PBN materials, this 
application greatly expanded the de?nition of potentially 
useful PBN compounds to include PBN, and derivatives 
thereof of the formula 
45 
H 
wherein 
55 X is phenyl, imidazolyl, phenothiazinyl 0 
60 
n=-5, preferably 1-3; 
65 R2=independently (can vary within the molecule) halo 
gen, alkyl, oxvalkyl, alkenyl, oxyalkenyl, OH, NH2, 
NI-IZ, N22, NO, 
5,475,032 
—SO3H, ——OSO3H, SH, —S(alkyl), —S(alkenyl, and 
haloalkyl, speci?cally including —CF3; 
A:0 or S; and 
Z is a C1 to C6 straight, branched, alkyl or cyclic group; 
and 
Y is a tert-butyl group that can be hydroxylated or 
acetylated at one or more positions; phenyl or 
(R2), 
PBN was stated to be the most preferred compound at that 
time, being said to have no measurable e?‘ect on normal or 
uninjured cells, and a number of derivatives were also stated 
to be useful, including hydroxy derivatives, especially 2-, 3 
or 4-hydroxyphenyl t-butyl nitrone and phenyl (mono-, di 
or trihydroxy) tert-butyl nitrone; PBN esters, especially 
esters which release 2-, 3-, or 4-hydroxyphenyl t-butyl 
nitrone such as acetoxy derivative; 2-, 3-, or 4-carboxyphe 
nyl t~butyl nitrone; phenyl hydroxybutyl nitrone; alkoxyl 
derivatives, especially alkoxyl derivatives which release 2-, 
3-, or 4-hydroxyphenyl t-butyl nitrone, for example, the 2-, 
3-, or 4-methoxyphenyl derivatives of PBN; and acetamide 
derivatives, especially acetarnide derivatives which release 
2-, 3-, or 4-aminophenyl t-butyl nitrone; diphenyl nitrone 
(PPN) and the analogous diphenyl nitrone derivatives; 
N-tert-butyl-u-(4-nitrophenyl) nitrone; and N-tert-butyl-tx 
(Z-sulfophenyl) nitrone. 
STATEMENT OF THE INVENTION 
It has now been discovered that one particular PBN 
derivative and its salts have unexpectedly superior pharma 
cological properties. Although this derivative, 2,4-disulfonyl 
PBN, falls within the broad family of materials generally 
described in the aforementioned WO 92/022290 publication, 
it is not speci?cally disclosed. Neither are its advantageous 
properties predicted. 
The present compound with its two sulfonate groups was 
expected to exhibit improved water solubility but was also 
expected to exhibit poor transport across the blood/brain 
barrier because of its lipophobic character. However, when 
the present compound was made and tested in vivo, it 
showed an unexpected increase in e?icacy as compared to 
PBN. This increase in eliicacy occurred along with an 
increase in potency as compared to PBN. In direct contrast 
to this marked increase in potency and e?icacy there was a 
marked and highly signi?cant decrease in toxicity as com 
pared to PBN. 
These results were unexpected because in the general 
literature on structure/activity relationships within speci?c 
de?ned families of compounds therapeutic potency typically 
covaries with toxicity. Thus, most related compounds main 
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tain their ratio of therapeutic potency to toxicity. In contrast, 
the compound of this invention deviates from this expected 
relationship when its potency increased and its toxicity 
decreased relative to closely related analogs. 
Accordingly, in one aspect, the invention provides the 
PBN-disulfonyl compound 
SOQH 
and its pharmaceutically acceptable salts. 
In a second aspect, the invention provides parenterally-, 
e.g. intravenously- and orally-administrable pharmaceutical 
compositions having this compound or its salt as active 
ingredient. 
In a third aspect, this invention provides a method for 
treating a patient who is suffering from a condition involving 
acute oxidative damage to the central nervous system, such 
as a patient who has suffered a stroke, in which a pharma 
ceutical composition based on this compound or its salt is 
administered parenterally, e.g. intravenously. 
In a fourth aspect, this invention provides a method for 
treating a patient suffering from a condition characterized by 
protracted low grade oxidative stress upon the central ner 
vous system and progressive loss of central nervous system 
function. In this method, a pharmaceutical composition 
based on this compound or its salt is administered parenter 
ally, e.g. intravenously or preferably orally. 
In a ?fth aspect, this invention provides a method for 
reducing or ameliorating the side-eifects arising from oxi 
dative damage produced in a patient by cancer therapy. In 
this method a pharmaceutical composition based on this 
compound or its salt is administered parenterally, e.g. intra 
venously or orally. 
DETAILED DESCRIPTION OF THE 
INVENTION 
This Detailed Description is arranged into the following 
sections: 
Brief Description of Drawings. 
The Compounds and Salts. 
Compound Preparation. 
Pharmaceutical Compositions. 
Conditions Treated and Treatment Regimens. 
Examples. 
BRIEF DESCRIPTION OF THE DRAWINGS 
In this speci?cation reference will be made to the accom 
panying drawings in which 
FIG. 1 is a schematic ?ow chart of the reactions used to 
prepare the compound. 
FIGS. 2 (A, B and C) and 3 (A, B, C, and D) are two sets 
of graphs illustrating the undesirable change in animal body 
thermal regulatory ability which occurs as a function of dose 
level with a prior art nitrone radical trapping agent and 
contrasting this with the lack of such undesired toxic effect 
with the compound of the invention. 
FIG. 4 (A, B, C, and D) is a set of four graphs demon 
strating the superiority of the compound of the invention as 
5,475,032 
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compared to a closely related prior art nitrone compound in 
the treatment of gradual neurodegeneration conditions (such 
as Alzheimer’ s disease) as illustrated by their relative ability 
to interfere with beta amyloid protein‘s inactivation of key 
enzymes in solution. 
FIG. 5 is a graph illustrating the effectiveness of the 
compound of the invention in reducing the ultimate infarct 
volume observed following middle cerebral artery occlusion 
in rats. 
FIGS. 6 (A, B and C) are three graphs illustrating the 
ability of the compound of the invention to reduce the 
side-effects in animals of high dose levels of anticancer 
agents. 
THE COMPOUND AND SALTS 
The compound of this invention is 2,4-disulfonyl ot-phe 
nyl tertiary butyl nitrone. It is also referred to informally 
herein as “2,4-disulfonyl PBN” or “PBN 2,4-disulfonate." It 
exists in an acid form 
as a solid and in solution in low pH conditions. It also exists 
at higher pHs in an ionized salt form which can be shown as 
where X is a pharmaceutically acceptable cation. Most 
commonly, this cation is a monovalent material such as 
sodium, potassium or ammonium, but it can also be a 
multivalent alone or cation in combination with a pharma 
ceutically acceptable monovalent anion, for example cal 
cium with a chloride, bromide, iodide, hydroxyl, nitrate, 
sulfonate, acetate, tartrate, oxalate, succinate, palmoate or 
the like anion; magnesium with such anions; zinc with such 
anions or the like. When these combinations of a polyvalent 
cation and a monovalent anion are illustrated in structural 
formulae, herein, the monovalent anion is identi?ed as “Y”. 
Among these materials, the free acid and the simple 
sodium, potassium or ammonium salts are most preferred 
with the calcium and magnesium salts also being preferred 
but somewhat less so. 
COMPOUND PREPARATION 
As detailed in FIG. 1 and demonstrated in Example 1, the 
compound of this invention can be prepared by a two step 
reaction sequence. In the ?rst step, commercially available 
tertiary butyl nitrate (2 -methyl-2-nitropropane) is converted 
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to the corresponding n-hydroxyl amine using a suitable 
catalyst such as an activated zinc/acetic acid catalyst or an 
aluminum/mercury amalgam catalyst. This reaction can be 
carried out in 0.5 to 12 hours and especially about 2 to 6 
hours or so at a temperature of about 15° to 100° C. in a 
liquid reaction medium such as alcohol/water mixture in the 
case of the zinc catalyst or an ether/water mixture in the case 
of the aluminum amalgam catalyst. 
In the second step, the freshly formed hydroxylamine is 
reacted with 4-formyl-l ,3 -benzenedisulfonic acid, typically 
with a slight excess of the amine being used. This reaction 
can be carried out at similar temperature conditions. This 
reaction is generally complete in 10 to 24 hours. 
The product so formed is the free acid and is characterized 
by a molecular weight of 89 g/mole. It is a white powdery 
material which decomposes upon heating. It is characterized 
by a solubility in water of greater than 1 gram/ml and a 1H 
NMR spectrum in D20 of 8.048 ppm (dd, 8.4, 1.7 Hz); 8.836 
ppm ((1, 8.4 Hz); 8.839 ppm (d, 1.7 Hz); 8.774 ppm (s). 
The various salts can be easily formed by admixing the 
free acid in aqueous medium with two equivalents of the 
appropriate base, for example, KOH for the potassium salt, 
and the like. 
PHARMACEUTICAL COMPOSITIONS 
The compound (including its salts) can be formulated into 
pharmaceutical compositions suitable for oral or parenteral, 
e.g. intravenous or intramuscular injection administration. 
The compositions for oral administration can take the 
form of liquid solutions or suspensions, powders, tablets, 
capsules or the like. In such compositions, the PBN 2,4» 
disulfonate or its salt is usually a minor component (0.1 to 
say 50% by weight) with the remainder being various 
vehicles or carriers and processing aids helpful for forming 
the desired dosing form. A liquid form may include a 
suitable aqueous or nonaqueous vehicle with buffers, sus 
pending dispensing agents, colorants. flavors and the like. 
A solid form may include, for example, any of the 
following ingredients, or compounds of a similar nature: a 
binder such as microcrystalline cellulose, gum tragacanth or 
gelatin; an excipient such as starch or lactose, a disintegrat 
ing agent such as alginic acid, Primogel, or corn starch; a 
lubricant such as magnesium stearate; a glidant such as 
colloidal silicon dioxide; a sweetening agent such as sucrose 
or saccharin; or a ?avoring agent such as peppermint, sugar, 
methyl salicylate, or orange ?avoring. 
In the case of injectable compositions, they are commonly 
based upon injectable sterile saline or phosphate-bu?’ered 
saline or other injectable carriers known in the art. Again the 
active nitrone is typically a minor component, often being 
from about 0.05 to 10% by weight with the remainder being 
the injectable carrier and the like. 
CONDITIONS TREATED AND TREATMENT 
REGIMENS 
The conditions treated with the 2,4-disulfonyl PBN gen 
erally fall into three groups. The ?rst includes conditions 
involving acute intense oxidative damage to a region of the 
central nervous system. Examples of these conditions 
include stroke, conditions associated with stroke, concus 
sion and subarachnoid hemorrhage. In this setting, the 
compound is administered in a manner designed to get the 
drug into the patient’s bloodstream as quickly and directly as 
possible. This usually means intravenous administration. 
5,475,032 
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Intravenous dose levels for treating these conditions range 
from about 0.1 mg/kg/hour to at least 10 mg/kgl'hour, all for 
from about 1 to about 120 hours and especially 24 to 96 
hours. A preloading bolus of from about 10 to about 500 mg 
may also be administered to achieve adequate steady state 
levels. 
While intravenous administration is preferred, other 
forms of parenteral administration, such as intramuscular 
injection can be used, as well. In this case, similar dose 
levels are employed. An unexpected and key advantage of 
2,4-disulfonyl PBN is that it can be administered at vastly 
higher levels than are possible with PBN itself. As will be 
shown in the Examples, doses of up to 1000 mg/kg/hour and 
higher or intravenous bolus doses of from 10 to 2500 mg/kg 
have been demonstrated to be possible with 2,4-disulfonyl 
PBN or its salts while with PBN itself death or acute toxicity 
results from such doses. With 2,4-disulfonyl PBN there is an 
unexpected positive continuance of the dose/response curve 
in these high dose levels with the clear message that intense 
heavy dosing immediately post stroke or other trauma may 
in many cases provide a major positive impact upon recov 
cry. 
The second group of conditions which respond favorably 
to 2,4-disulfonyl PBN treatment are conditions character 
ized by protracted low grade oxidative stress upon the 
central nervous system and gradual progressive central 
nervous system function loss. These conditions include 
Alzheimer’s disease, Parkinson‘s disease, amyotrophic lat 
eral sclerosis (ALS), multidnfarct dementia, retinopathy and 
the like. Each of these conditions is characterized by a 
progressive loss of function. 2,4-disulfonyl-PBN or its salts, 
when administered orally or parenterally, e.g. intravenously, 
can slow and possibly reverse the loss of function. If 
parenteral, e. g. intravenous administration is desired, similar 
levels to those used with acute conditions but at the lower 
end of the ranges are generally used. 
In these cases, the regimen for treatment may stretch over 
many months or years so oral dosing is preferred for patient 
convenience and tolerance. With oral dosing, one to three 
oral doses per day, each from about 0.02 to about 50 mg/kg 
are called for with preferred doses being from about 0.04 to 
about 5.0 mg/kg. 
Of course, one can administer 2,4-disulfonyl PBN as the 
sole active agent or one can administer it in combination 
with other agents. This leads to a third application for this 
compound. 
A third set of conditions which respond to treatment with 
2,4-disulfonyl PBN are the side-effects which arise in 
patients from oxidative damage produced by cancer (neo 
plastic disease) therapy. The therapy which produces the 
oxidative damage (and thus the side effects) includes radia 
tion (e.g. gamma radiation) therapy and therapy with oxi 
dative~damage causing chemotherapeutic agents. Examples 
of these agents include antibiotics such as daunorubicin, 
doxorubicin and bleornycin; procarbazine; nitrogen mus 
tards such as ifosfamide, melphalan and chlorambucil; alky 
lating agents; antimetabolites; hormones and antagonists. 
Administration of 2,4-disulfonyl PBN can have the effect 
of reducing patient discomfort during these therapies. In 
addition, administration of the compound of this invention 
can increasing patients’ ability to tolerate these therapies. 
Often the side effects of therapies force the discontinuance 
of these therapies or prevent the administration of optimal 
high doses or rapid frequencies of these therapies. In some 
cases these side effects are devastatingly destructive and 
lead to heart failure and other major function loss. In tests in 
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animals it has been observed that the compound of the 
invention can improve patient tolerance of these antine 
oplastic disease treatments. 
In this therapy, the compound of the invention may be 
administered before, during and after the radiation or che 
motherapy is administered. Administration may be 
parenteral or oral or by any other method which will permit 
the 2,4~disulfonate PBN to enter the patient’s bloodstream. 
A positive dose-response relationship has been observed. 
As such, and bearing in mind the severity of the side effects 
and the advantages of providing maximum possible protec 
tion or amelioration, it may be desired in some settings to 
administer large amounts of 2,4 -disulfonyl PBN such as 
those described above for the acute intense oxidative CNS 
damage conditions. In other settings lower doses, such as 
those set forth for the progressive neuronal disease therapy, 
may be used. 
The following are examples of representative administra~ 
tion regimens: In monotherapy (adriarnycin alone) two 
representative dose combinations are 10-600 mg Compound 
I per square meter area plus 60 mg adriamycin per square 
meter of surface area with adriamycin dosing occurring 
every seven or twenty-one days. Compound I may be 
administered before the adriamycin, for example, up to 60 
minutes before, at the same time or after, such as hours after 
and on subsequent days. The pediatric dose is typically 
lower for both drugs. Higher doses may be used for treat 
ment of multidose resistant tumors. 
EXAMPLES 
Example 1 
Synthesis of 2,4-disulfonylphenyl-N-t-butylnitrone 
(Compound “I” in subsequent Examples). This preferred 
synthesis is based on the work by R. H., Hinton and E. G. 
Janzen (J. Org. Chem,. 57:2646—265l, 1992). As shown in 
FIG. 1 it involves the condensation of an aldehyde with a 
hydroxylamine. The hydroxylamine is unstable and is pre 
pared fresh on the day of use using an activated zinc catalyst. 
The synthesis is as follows: 
Prerequisite Chemicals 
. 95% Ethanol 
. 2-Methyl-2-nitropropane 
. Zinc dust 
. Glacial acetic acid 
. Diethyl ether 
. Saturated sodium chloride 
. Magnesium Sulfate, Anhydrous solid 
4-Formyl- l ,3-benzenesulfonic acid 
g/mole), disodium salt, hydrate 
9. Methanol 
l0. Dichloromethane 
POQCKUi-ALDMH (MW 310.21 
Procedure 
A. Preparation of N-t-Butylhydroxylamine 
l. A 500 ml three neck round bottom ?ask is equipped 
with a magnetic stir bar, thermometer adapter, ther 
mometer, and addition funnel. 
2. 95% ethanol (350 ml) was added to the ?ask and cooled 
to 10° C. in an ice bath. 
3. 2-Methyl-2-nitropropane (6.18 g, 0.060 mole), and zinc 
5,475,032 
dust (5.89 g, 0.090 mole) were added in single portions. 
4. Glacial acetic acid (10.8 g, 0.180 mole) was placed in 
the addition funnel and added dropwise at such a rate 
with vigorous stirring to maintain the temperature 
below 15° C. 
5. The ice bath was removed and mixture was stirred for 
3 hrs at room temperature. 
6. The solvent was stripped from the mixture, leaving 
t-butylhydroxylamine, zinc acetate, and water. 
7. Dichloromethane (50 ml) was added and the mixture 
?ltered through a Buchner funnel. 
8. The zinc acetate cake left on the ?lter paper was washed 
with 2X25 ml dichloromethane. 
9. Water was separated from the ?ltrate in a separatory 
funnel and the organic layer dried over magnesium 
sulfate. 
10. The magnesium sulfate was removed by ?ltering 
through ?uted ?lter paper, then dichloromethane 
stripped o? by rotary evaporation. 
11. The product (100% yield=5.34 g), a viscous liquid, 
was dissolved in methanol (50 ml) for use in part B. 
B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone 
l. A 3-r1eck 250 ml round bottom ?ask was set up with a 
stir bar, a gas dispersion tube, an addition funnel, and 
a Friedrichs condenser cooled with recirculating ice 
water. 
2. To the ?ask were added 200 ml of methanol, 4-for'myl 
1,3-benzenedisulfonic acid (9.31 g, 30 mmoles) and 
N-t-butylhydroxylamine (25 ml of the methanol solu 
tion from part A, 30 moles theoretical). 
3. The reaction was heated to re?ux with a heating mantle 
while bubbling the reaction with nitrogen with stirring. 
4. The mixture was re?uxed for 2 hours. 
5. The remainder of hydroxylamine from part A was 
added. 
6. Re?uxing was continued with nitrogen bubbling for at 
least 18 hours, but not more than 24 hours. 
7. The hot reaction mixture was ?ltered on a Buchner 
funnel, and the solid washed with hot methanol. 
8. The methanol was stripped off by rotary evaporation to 
a yellow. viscous oil. 
9. Hot 1:1 ethanol:acetone (200 ml) was added and the 
mixture heated to dissolve the oil. 
10. The solution was cooled to crystallize the product. 
11. The product was collected on a Buchner funnel and 
dried under vacuum overnight. 
12. The reaction typically gives 75% yield of Compound 
I, a white powder. 
Example 2 
Alternate Synthesis of 2,4—disulfonylphenyl-N-t-butylni 
trone (Compound I). This is an earlier-developed method 
which used to prepare samples of the compound used in 
several of the experiments reported in the Examples of this 
speci?cation. The product of this Example is identical in all 
ways to the product of Example 1. This synthesis method is 
as follows: 
Prerequisite Chemicals 
1. Aluminum Foil, cut into 5 cm wide strips and rolled in 
a ca. 1 cm diameter cylinder 
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. Mercury (II) Chloride (9.68 g in 476 ml water) 
. Ethanol 
. Ether (6 l) 
. Pure Water 
. 2-Methyl-2-nitropropane 
. Sodium Hydroxide, 2M (80 g in l 1 water) 
. Magnesium Sulfate, Anhydrous solid 
4-Formyl-l,3-benzenesulfonic acid (MW 310.21 
g/mole) 
Procedure 
A, Preparation of N-t-Butylhydroxylamine 
1. Aluminum foil cylinders were dipped into HgCl2 
solution for 15-30 seconds, then dipped in ethanol, 
then dipped in ether and then placed into a 5 l ?ask 
containing 500 ml of diethyl ether and 21.4 ml of water. 
2. The ?ask was ?tted with a 250 ml pressure-equalizing 
dropping funnel, a mechanical stirrer, a nitrogen inlet, 
and a Friedrichs condenser cooled with recirculated ice 
water. 
3. The mixture was stirred for 10 minutes. 
4. 2-Methyl-2-nitropropane (71.68 g, 75.5 ml) was added 
using the dropping funnel at such a rate as to maintain 
a vigorous re?ux. 
NOTE: Addition must be completed in less than 20 minutes 
or the yield drops signi?cantly. 
5. As the addition proceeded, ether was added in 500 ml 
portions. This was done to maintain as high a concen 
tration of product as possible without the formation of 
a gel. Up to 2 l of ether can be added with no deleterious 
effects on the yield. 
6. Once addition of 2-methyl-2-nitropropane was com 
plete, the reaction was stirred for an additional 30 
minutes. 
7. The resulting gray suspension was suction ?ltered in 3 
batches to remove aluminum salts. 
8. Each ?lter cake was washed with l l of ether. 
9. The combined either layers were washed with 300 ml 
of 2M NaOH, then dried (MgSO4), and concentrated in 
vacuo to leave a soft white solid. 
10. The solid melts just above room temperature, but 
could be dried further in a vacuum oven (no more than 
a few minutes), leaving 38 to 45 g of solid. 
11. The solid can be used as is or was puri?ed by 
recrystallization from pentane. 
12. Molecular weight-89 g/mole. 
B. Preparation of 2,4-disulfonylphenyl-N-t-butylnitrone 
l. A 250 ml ?ask was equipped with a stir bar and a 
Friedrichs condenser cooled with recirculated ice 
water. 
2. The ?ask was charged with 71.8 ml of methanol, 14.5 
g of 4-formy1-l,3 -benzenedisulfonic acid (46.7 
mmoles, 1 eq.). and 5.0 g of N-t-butylhydroxylamine 
(56.2 mmoles, 1.2 eq.). 
3. The mixture was re?uxed overnight. 
4. The reaction product was transferred to round-bottom 
?ask and rotovaped to dry. 
5. The solid residue was mashed with ether, the ether was 
decanted oif (yellow). 
6. Step 5 was repeated. 
7. Product (“Compound I") was crystallized from metha 
5,475,032 
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nol following a hot methanol ?ltration to remove 
insoluble precipitates and recrystallized twice from 
methanol. 
Example 3 
A series of experiments were carried out to compare in 
vivo the e?icacy of 2,4 disulfonyl PBN (“Compound I”), 
PBN, and two monosulfonate PBN compounds as agents for 
protecting against neuron loss following brain ischernia and 
reperfusion injury. The test procedure is that reported by W. 
Cao, J. M. Carney, A. Duchon, R. A. Floyd and M. Chevion 
as “Oxygen free radical involvement in ischemia and rep’ 
erfusion injury to brain, Neuroscience Letters, 88 (1988), 
233. In the experiments a test compound was administered 
to groups of six gerbils i.p. as a single dose 30 min before 
5 min bilateral carotid occlusion. The density of neuronal 
nuclei in a 100 micron was measured. Two controls were 
present-controls which received no test compound and 
controls which received no test compound and no brain 
ischernia. As illustrated in Table 1. the compound of the 
invention showed unexpected advantages as compared to the 
prior art compounds. First, it is seen that at low dose levels, 
such as 3.2 mg/kg, compound I is 2-3 times as potent at 
preventing neuronal loss. At high dose levels it is seen that 
Compound I is able to achieve complete protection against 
neuronal loss as the test brains showed neuronal densities 
identical to the non-ischemic controls. The prior art com 
pounds are either toxic at these dose levels or showed 
signi?cantly lower degrees of protection. These results show 
a clear increase in potency for neural protection for com 
pound I compared to PBN and two closely related analogs 
and an unexpected decrease in toxicity compared to PBN. 
TABLE l 
Neuronal nuclei/100 micron ?eld 
2 3- Cmpd. 
PBN sulfo sulfo 1 
Non-ischemic control 4.21 4.21 4.21 4.21 
(.43) (.43) (.43) (.43) 
Ischernic control 058 0.58 0.58 0.58 
(.28) (.28) (.28) (.28) 
3.2 rug/kg 0.43 0.73 0.35 1.43 
(.18) (.34) (.21) (.31) 
10 mglkg 1.13 0.68 0.31 2.57 
(.39) (.31) (.40) (.25) 
32 mglkg 1.83 0.73 1.63 3.53 
(.21) (.31) (.35) (.41) 
50 mg/kg 3.11 1.01 1.63 4.11 
(.29) (.61) (.35) (.43) 
100 mg/kg 3.68 0.93 1.93 4.18 
(.71) (.53) (.39) (.49) 
320 mglkg 3.78 1.11 1.78 4.23 
(.43) (.41) (.40) (.39) 
1000 mg/kg Toxic 0.98 1.58 4.11 
(.43) (.38) (.41) 
3200 mg/kg Toxic -—- —~ 4.18 
Example 4 
A series of experiments were conducted in which com 
pound l was compared to PBN and two sulfonate analogs in 
post-ischernia treatment. The general method described in 
example 1 was used but the test compounds were adminis 
tered i.p. as a single dose 30 min after reperfusion following 
5 min ischemia. The results are summarized in Table 2. 
Table 2 shows that the compound of the invention is again 
more potent at low doses and more potent and less toxic at 
high doses. Also again, toxicity interferes with the ability of 
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the prior art compounds to go to high doses at which levels 
the compound of the invention provides dramatically effec 
tive therapy. 
TABLE 2 
Neuronal nuclei/100 micron field 
2 3 Cmpd. 
PBN sulfo sulfo I 
Non-ischemic control 4.18 4.18 4.18 4.18 
(.59) (.59) (.59) (.59) 
lschemic control 0.85 0.85 0.85 0.85 
(.19) (.19) (.19) (.19) 
32 mg/kg 1.09 ND ND 1.83 
(.31) (41) 
50 mglkg 1.85 0.68 0.73 2.73 
(.49) (.31) (.34) (.39) 
100 mg/kg 2.11 0.78 1.09 3.41 
(.51) (.23) (.48) (.37) 
320 mglkg 2.25 0.81 0.93 3.55 
(-43) (31) (48) 
1000 rug/kg Toxic ND ND 3.68 
(‘39) 
Example 5 
Compound I is compared with PBN to determine the 
relative elfectiveness for protection of neuronal loss when 
administered i.v. 60 min after reperfusion onset following 5 
min ischemia in gerbils using the general test method 
described in Example 1.. The results are summarized in 
Table 3. and illustrate that compound 1 is of signi?cantly 
greater therapeutic bene?t in a clinical treatment setting 
following injury to the brain. 
TABLE 3 
mg/kg single dose 
N = 6 per group 0.0 0.5 1.0 10 
Saline, no ischemia 4.11 — — — 
(428) 
saline, ischemia 0.93 — — ~— 
(.17) 
PBN — 0.83 1.07 1.23 
(.23) (.29) (.31) 
Compound 1 — 1.25 1.75 2.43 
(.19) (.28) (.31) 
Neither PBN nor Compound I. had an effect on neuronal 
density in control gerbils without brain injury. 
Example 6 
Brain injury can manifest itself as behavioral changes. In 
this experiment, young adult (3-4 months of age) gerbils 
were tested to determine their ability to perform an S-ann 
maze test 24 hours following an ischemic event as described 
in Example 1. As compared to nonischemic animals, when 
untreated they committed many more errors. PBN and 
compound I were administered to some of the test animals. 
As detailed in Table 4. gerbils treated with high doses of 
compound I had error levels indistinguishable from those of 
nonischemic animals. PBN was less eifective. This shows 
that compound I can protect against the loss of temporal] 
spatial short term memory following ischernia (24 hours 
post) errors in S-arm radial maze test of young gerbils 
following 5 min ischemia. 
5,475,032 
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TABLE 4 TABLE 7 
mg/kg/hr for 24 hours % Survival mg/kg 
N = 6 per group 0.0 L0 32 50 I00 5 n = 20 mice 320 560 1000 3000 l0000 
Control 4.1 — _ - PBN 100 25 0 0 0 
(.33) Compound I 100 100 100 100 100 
Postischemic 37.6 — -— -— 
(4.85) 
PBN — 29.3 18.19 6.23 5.83 10 
(7.27) (5.83) (.71) (.49) Example 10 
Compoundl - 14.63 7.19 4.28 4.11 _ 
(331) (.31) (19) U9) Another undesirable systemic effect which has been 
observed in vivo with nitrone radical traps is a depression in 
body temperature. This toxicity can have serious health 
15 consequences and also can complicate diagnosis of other 
Example 7 conditions. As detailed in FIGS. 2 and 4, the compound of 
this invention was administered to mice and gerbils at levels 
The ability of the compound of the invention to reduce as high as 1000 mg/kg with no measurable temperature 
infarct volume following an ischemic event was determined. decrease_ In contrast’ the compound of the an, pBN’ gave up 
As detailed in Table 5. it was observed that while PBN and 20 to an 30 C_ dacrease in body temperature at a does of only 
compound I were both effective at low doses, at high doses 500 [mg/kg 
I gave the best protection and PBN was toxic. Table 5 shows 
the infarct volume observed when test compound was Example 11 
administered i.v. 60 min after middle cerebral occlusion and i _ _ 
continued for 24 hours in C57BU6J mice“ 25 The compound of the lnvention was tested to detemune 
its e?ectiveness in the treatment of conditions characterized 
TABLE 5 by protracted low grade oxidative stress upon the central 
_ nervous system and gradual progressive central nervous 
Pwmamm Mam v°lume ‘" “"“3 system function loss by testing its effectiveness in a model 
(mg/kw) Q0 1.0 10 100 30 for Alzheimer’s disease (“AD“). This model has the follow 
ing basis: Recent studies have demonstrated that there is an 
C‘IPIIDIIYMSCPCmia 0 rr - — age-associated increase in protein oxidation and loss of 
same’ ‘Schema 2(3) — — _ enzyme activities in the brain of aged individuals. Tissue 
PEN _ 17.7 138 Toxic cultures of ?broblasts from aged individuals and red blood 
(2.8) (2.3) 35 cells of different ages both show an exponential increase in 
Compuuudl - 16,3 12-7 8-3 protein carbonyl content (a measure of protein oxidation) 
(1'7) (3'93) (‘71) and a decrease in marker enzyme activities. Brain protein 
oxidation progressively increases over the life span of the 
individual. 
Example 8 40 The role of abnormal amyloid precursor peptide process 
ing and metabolism in AD has also been explored in a 
In this study, compound I and PBN are compared for their number of different models. In vitro studies using embryonic 
ability to impart lethality protection (% survived) in aged hippocarnpal neuronal and nouronallglial cultures have dom 
gerbils (18-24 months of age, n=12/gr()up) from 10 min onstrated that BAP l-40 produces cytotoxicity over an 
ischemia when given 30 min before ischemia. As shown in 45 “tended period Of (to-incubation. When this peptide is 
Table 6. compound I is superior at all dose levels and infused into rat brains, lesions are produced. Some of the 
achieved complete protection at high levels while PBN is proposed breakdown fragments of BAP are also neurotoxic 
only partially effective. [c.g. [SAP (25-35)]. The neurotoxicity appears to be both 
mediated via glutamate receptors, and also by non-glutamate 
TABLE 6 50 receptors mechanisms. Confocal microscopy studies of neu 
Pmmatmam ronal cultures_have_ demonstrated that exposure to BAP 
(mg/kg) on 10 32 m0 320 (1-40) results in oxidative stress [Dichloro?uorescem and 
increased intracellular free calcium Fora-2]. 
gang‘: 4'; — — “ It has been demonstrated that BAP fragments can directly 
— 50 75 92 . . . . . 
compoundl _ 50 75 m0 100 55 inactivate glutanune synthetase (GS) and creatine kmase 
(CK) in tissue extracts and in cultured hippocampal neurons 
and glia (See A and B in FIG. 4). A and B of FIG. 4 present 
the dose-related inactivation of glutarnine synthetase and 
Exam 1 9 creatine kinase by AP (25-35). Cytosolic fractions from 
p e . . . . 
60 gerbil neocortex were prepared and enzyme activities deter 
An important advantage of the compound of this inven- mined. Samples were incubated in the presence of different 
tion as compared to the art-taught compound, PBN, is its concentrations of the peptide for 10 min prior to assay. Solid 
markedly diminished toxicity. As detailed in Table 7. acute symbols represent the effects of the naturally occurring 
lethality in C57BL/6L mice was determined based upon 25-35 fragment. Open circles indicate that the reverse 
varying sizes of single i.p. doses of nitrone. PBN showed 65 sequence (32-25) had no effect on enzyme activity. Open 
signi?cant toxicity at 560 mg/kg dose levels. Compound I 
showed no toxicity at doses nearly twenty times as great. 
triangles indicate that the scrambled amino acid sequence 
also had no eifect on enzyme activities, compared to the 
5,475,032 
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eifect of 25-35. Each point is the mean (+/- s.e.) of 5 
observations. BAP derived and other cellular sources of free 
radicals are an important determinant of the initiation and 
progression of AD. 
As demonstrated in C and D in FIG. 4, compound I and 
PBN each show the ability to protect GS and CK against the 
effects of [SAP fragments. C and D of FIG. 4 present the 
protective effects of co-incubation of the cytosolic fractions 
with BAP 25-35 (0.4 mg/ml) in combination with di?ercnt 
concentrations of PBN (open circles) or compound I (closed 
circles). Each point is the mean (+/— s.e.) of 3 observations. 
As can be seen in C and D, compound I gives complete 
protection and in fact might even be able to reverse the 
effects of oxidation. In contrast, PBN’s effectiveness is quite 
limited as it is asymptotically leveling out at a substantially 
incomplete level of protection. 
Example 12 
Experiments were carried out to further demonstrate the 
effectiveness of the compound of the invention in preventing 
central nervous system damage caused by stroke. 
Rat Focal Ischernia Results. 
A pair of studies were done to determine the e?icacy of 
Compound I in a rat focal ischernia model. In this model, 
Sprague Dawley rats (200-300 g) underwent a permanent 
middle cerebral artery occlusion (MCAO) to induce a focal 
stroke. Compound I was administered after the permanent 
occlusion as ?rst an intraperitoneal (i.p.) bolus dose and then 
by intravenous (i.v.) continuous infusion during the remain 
ing time up to 24 hours post stroke. The doses of Compound 
I used were either 100 mg/kg,j.p., followed by 4.2 mglkg/hr, 
i.v., or 10 mglkg, i.p., followed by 0.42 mglkg/hr, i.v. 
The rats were sacri?ced 3 days post stroke, the tissue was 
processed histologically using triphenyltetrazolium staining 
techniques, and the infarct volume, the area of total cell 
necrosis, was quantitated using image analysis. The results 
of these experiments are shown graphically in FIG. 5 and 
demonstrate that Compound I provided signi?cant protec 
tion, approximately 70%, in both studies. 
Comparison with Results in the Literature. 
Similar data have been reported recently for the com 
pound NOT of this invention, PBN, by Cao and Phillis 
(Brain Research 664: 267-272, 1994). In their studies, rats 
underwent a permanent middle cerebral artery occlusion 
(MCAO) and a common carotid artery occlusion. The PBN 
was administered i.p. at 100 mglkg at various times post 
stroke. The rats were sacri?ced 2 days post stroke and the 
infarct volume was quantitated using triphenyltetrazolium 
stain. 
When PBN was administered at 0.5, 5, 17, 29 and 41 
hours post stroke, or at 5, 17, 29, and 41 hours post stroke, 
the infarct volume was reduced in each case by approxi 
mately 50%. The cumulative dose of PBN administered to 
achieve 50% protection is at a minimum 4 times the amount 
of Compound I required for 70% protection. Thus, Com 
pound I is far superior to PBN in offering protection in the 
rat MCAO focal ischemia model. 
Example 13 
In this Example the compound of this invention (Com 
pound I) was evaluated to determine its ability to ameliorate 
oxidation-caused side effects of anticancer therapy. 
Adriamycin Studies 
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Adriamycin is a widely used anticancer agent. It is known 
to be very effective but it is also known to have serious side 
elfects arising from its tendency to cause oxidative damage. 
These side eifects include causing serious levels of cardiac 
damage at high dose levels. These side effects have often 
limited the use of this agent or limited the dose levels that 
can be employed to levels which are below those desired for 
maximum antineoplastic disease effectiveness. 
Experiments were carried out to demonstrate that the 
compound of the invention is e?‘ective at reducing the side 
effects of anticancer agents such as adriamycin and permit 
ting higher dose levels of adriamycin to be tolerated by 
animals. 
C57BL/6l and DBA/2J male mice (35-40 g) were tested 
for the acute lethal effects of adriamycin and the prevention 
of acute lethality by pretreatment doses of Compound I. 
Mice were injected with either saline or Compound I 30 
minutes prior to administration of adriamycin. All injections 
were intraperitoneal. The acute lethality of adriamycin 
ranged from 10 to 30 mglkg. The LDso for adriamycin in 
these tests was found to be 25 mglkg in both mouse strains. 
Compound I doses up to 300 mglkg, without adriamycin 
treatment, had no effect on survival in the two mouse strains. 
Pretreatment with 30 and 100 mglkg of Compound I 
produced dose related shifts in the adriamycin lethality dose 
effect curve. FIG. 6 shows the results obtained using the 
DEA/2] mouse. A dose of 100 mg/kg of Compound I 
produced a 5-fold shift to the right (in the direction of 
reduced lethality). Thus, the combination of Compound I 
with adriamycin resulted in a marked increase in the maxi 
mally tolerated dose. These higher doses are in the range that 
would elfectively kill multi-drug resistant tumors. 
Comparative Tests 
PBN pretreatment resulted in a slight shift to the right in 
the adriamycin does-effect curve. While the Compound 1 
dose could be increased to 300 mglkg in combination with 
adriamycin, there was an upper limit for this combination 
with PBN. A dose of PBN of 100 mglkg produced slight 
sedation and 300 mglkg yielded marked sedation and some 
combined toxicity 00-20% lethality). Compound l/adria 
mycin did not produce any combined toxicity at doses of 
Compound I of up to 300 mglkg. 
Example 14 
Safety Testing. 
Compound ] and PBN were tested for their acute toxicity 
in male Sprague Dawley (200-300 g) rats. The compounds 
were administered at 1000 mglkg, i.p., to groups of 6 rats. 
After 3 days lethality was assessed. Compound I caused no 
lethality, while PBN was lethal to 5 of the 6 rats used in this 
test. These data con?rm the gerbil data in that Compound I 
has higher safety than PBN. 
What is claimed is: 
1. A method for treating a patient who has suffered a 
stroke comprising administering to said patient an effective 
stroke treating amount of a pharmaceutical composition 
comprising the compound 2,4-disulfonyl ot-phenyl tertiary 
butyl nitrone in a pharmaceutically acceptable carrier. 
2. The method of claim 1 wherein the composition is 
administered parenterally. 
3. The method of claim 2 wherein the composition is 
administered intravenously. 
4. The method of claim 3 wherein the composition is 
administered in an amount of at least 0.2 mglkg/hour. 
5,475,032 
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5. The method of claim 1 wherein the composition is 
administered orally. 
6. A method for treating a patient who has su?'ered a 
stroke comprising administering to said patient an e?'ective 
stroke treating amount of a pharmaceutical composition 
comprising a compound of the formula 
in a pharmaceutically acceptable carrier. 
7. The method of claim 6 wherein the composition is 
administered parenterally. 
8. The method of claim 7 wherein the composition is 
administered intravenously. 
9. The method of claim 8 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
10. The method of claim 6 wherein the composition is 
administered orally. 
11. A method for treating a patient who has su?ered a 
stroke comprising administering to said patient an effective 
stroke treating amount of a pharmaceutical composition 
comprising a pharmaceutically acceptable salt of 
503 
in a pharmaceutically acceptable carrier. 
12. The method of claim 11 wherein the composition is 
admixed parenterally. ‘ 
13. The method of claim 12 wherein the composition is 
administered intravenously. 
14. The method of claim 13 wherein the composition is 
administered in an amount of at least 0.2 mg/kglhour. 
15. The method of claim 11 wherein the composition is 
administered orally. 
16. A method for treating a patient who has suffered a 
stroke comprising administering to said patient an effective 
stroke treating amount of a pharmaceutical composition 
comprising a compound of the formula 
803x 
wherein X is selected from the group consisting of Na, K, 
NH4, Ca Mg, Zn, ZnY, CaY and MgY, wherein Y is a 
pharmaceutically acceptable monovalent anion, in a phar~ 
maceutically acceptable carrier. 
17. The method of claim 16 wherein the composition is 
administered parenterally. 
18. The method of claim 17 wherein the composition is 
administered intravenously. 
19. The method of claim 18 wherein the composition is 
administered in an amount of at least 0.2 mg/kg/hour. 
20. The method of claim 16 wherein the composition is 
administered orally. 
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21. A method for treating a patient su?ering from a 
progressive central nervous system function loss comprising 
administering to said patient an elfective progressive central 
nervous system function loss treating amount of a pharma 
ceutical composition comprising the compound 2,4-disulfo 
nyl ot-phenyl tertiary butyl nitrone in a pharmaceutically 
acceptable carrier. 
22. The method of claim 21 wherein the composition is 
administered parenterally. 
23. The method of claim 22 wherein the composition is 
administered intravenously. 
24. The method of claim 23 wherein the composition is 
administered in an amount of at least 0.1 mg/kg/day. 
25. The method of claim 21 wherein the composition is 
administered orally. 
26. A method for treating a patient su?ering from a 
progressive central nervous system function loss comprising 
administering to said patient an effective progressive central 
nervous system function loss treating amount of a pharma 
ceutical composition comprising a compound of the formula 
in a pharmaceutically acceptable carrier. 
27. The method of claim 26 wherein the composition is 
administered parenterally. 
28. The method of claim 27 wherein the composition is 
administered intravenously. 
29. The method of claim 28 wherein the composition is 
administered in an amount of at least 0.1 mg/kglday. 
30. The method of claim 26 wherein the composition is 
administered orally. 
31. A method for treating a patient suifering from a 
progressive central nervous system function loss comprising 
administering to said patient an e?°ective progressive central 
nervous system function loss treating amount of a pharma 
ceutical composition comprising a pharmaceutically accept 
able salt of 
O 
$034 
in a pharmaceutically acceptable carrier. 
32. The method of claim 31 wherein the composition is 
administered parenterally. 
33. The method of claim 32 wherein the composition is 
administered intravenously. 
34. The method of claim 33 wherein the composition is 
administered in an amount of at least 0.1 mg/kg/day. 
35. The method of claim 31 wherein the composition is 
administered orally. 
36. A method for treating a patient suffering from a 
progressive central nervous system function loss comprising 
administering to said patient an e?’ective progressive central 
nervous system function loss treating amount of a pharma— 
ceutical composition comprising a compound of the formula 
5,475,032 
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wherein X is selected from the group consisting of Na, K, 
NH4, Ca, Mg, Zn, Zny, CaY and MgY, wherein Y is a 10 
pharmaceutically acceptable monovalent anion, in a phar 
20 
maceutically acceptable canier. 
37. The method of claim 36 wherein the composition is 
administered parenterally. 
38. The method of claim 37 wherein the composition is 
administered intravenously. 
39. The method of claim 38 wherein the composition is 
administered in an amount of at least 0.1 mglkg/day. 
40. The method of claim 36 wherein the composition is 
administered orally. 
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"2,4-disulfonyl‘l 
"2,4-disulfonyl" 
"2,4-disulfonyl" 
"2,4-disulfonyl" 
should 
should 
should 
should 
should 
read 
read 
read 
read 
read 
UNITED STATES PATENT AND TRADEMARK OFFICE 
CERTIFICATE OF CORRECTION 
PATENT NO. ; 5,475,032 Page 3 of 4 
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1NVENTOR(S) 1 JOHN M. CARNEY 
It is certified that error appears in the above-indentified patent and that said Letters Patent is hereby 
corrected as shown below: 
Column 7, line 31, "2,4—disulfonyl-PBN" should read 
-—2,4—disulfo—PBN—-. 
Column 7, line 43, "2,4-disulfonyl" should read —-2,4— 
disulfo—-. 
Column 7, line 48, "2,4-disulfonyl" should read --2,4— 
disulfo-—. 
Column 7, line 59, "2,4-disulfonyl" should read —-2,4 
disulfo--. 
Column 8, line 13, "2,4—disulfonyl" should read -—2,4— 
disulfo—-. 
Column 8, line 34, "2,4-disulfonylphenyl-N-t 
butylnitrone" should read --2,4-disulfophenyl—N-t 
butylnitrone——. 
Column 9, lines 56-57, "2,4-disulfonylphenyl-N-t 
butylnitrone" should read —-2,4-disulfophenyl—N-t— 
butylnitrone—-. 
Column 10, line 51, "2,4-disulfonylphenyl-N-t 
butylnitrone" should read -—2,4—disulfophenyl—N-t— 
butylnitrone--. 

